ANXA1 and atopic eczema: Supporting the last findings, in human keratinocytes stimulated under atopic dermatitis conditions, levels of both NLRP3 and ANXA1 were elevated, along with the release of IL-1β, and treatment with an ANXA1 mimetic peptide modulated IL-1β production and NLRP3 activation, highlighting the relevance of this interaction in cutaneous inflammation (40).